Comparison of memory B cell responses in Bangladeshi adults following single-dose and two-dose oral cholera vaccine, Shanchol^TM.

Authors

Pinki Dash, Aklima Akter, Nusrat Jahan, Golam Sarower Bhuyan, Polash Chandra Karmakar, Md Asif Ahsan, Mohammad Murshid Alam, Amena Aktar, Taher Uddin, Stephen B Calderwood, Fahima Chowdhury, Ashraful I Khan, Amit Saha, Edward T Ryan, Taufiqur Rahman Bhuiyan, Afroza Akter, Firdausi Qadri

Published in

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Pages 109219. Oct 31, 2026. Epub Oct 31, 2026.

Abstract

Oral cholera vaccines (OCVs) provide short-term protection against cholera. The objective of this study was to assess the immune responses after each dose of Shanchol^TM vaccine.
We included 120 adults (18-45 years old) in this study and compared responses following administration of the standard two-dose regimen (14 days apart, n=40), a single-dose regimen (n=40), and an alternate two-dose regimen (one month apart, n=40) for up to one year.
We found that all three groups of vaccinees developed prominent vibriocidal responses and plasma anti-lipopolysaccharide (LPS) IgG and IgA responses within seven days of vaccination, and vibriocidal responses remained elevated for more than one month. All groups of vaccinees developed IgA MBC responses to V. cholerae O1 LPS within 30 days of vaccination and remained detectable for 3 to 12 months. The cohort that received a single-dose of vaccine developed a significant IgG MBC response against V. cholerae O1 LPS at day 30. None of the groups exhibited an MBC response to O139 LPS compared with day 0.
Administering a single-dose induces comparable relevant immune responses as the two-dose regimen in 18-45 years old adults in highly cholera-endemic areas, such as Bangladesh. These findings may not be generalizable to children, immunologically naïve populations, or non-endemic settings.

PMID:
42966445
Bibliographic data and abstract were imported from PubMed on 01 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.